Avaliação da adesão ao mesilato de imatinibe de pacientes com leucemia mielóide crônica

Chronic Mielogenous Leukemia (CML) is a clonal hematologic disease that can be controlled with oral pharmacotherapy. One of the most important factors that influences the treatment is the patient adherence to the prescribed medication. The goal of this study was to compare the adherence of patients with CML treated with imatinib mesylate before and after the pharmaceutical intervention. The first phase of the study consisted on the application of two questionnaires: Morisky’s et al. (evaluate the adherence to treatment) and Svarstad’s et al. (evaluate patient behavior regarding adherence; the belief in the treatment and identify the presence of barriers to follow therapy). On the second phase each patient received a pharmaceutical intervention. Approximately three months later the two questionnaires were reapplied. The data obtained was analyzed by simple descriptive analysis and Wilcoxon’s test. In all 30 patients of an oncologic hospital were recruited and 24 completed the study. Before the intervention 15 participants had intermediate or low adherence according to Morisky et al. questionnaire; after intervention five had intermediate adherence and 19 high (p=0,005). According to Svarstad et al. questionnaire, before the intervention eight patients had potential non-compliance, 17 participants presented barriers to belief in the treatment and eigth presented barriers to follow therapy. After intervention, the results were, respectively: 11 (p = 0.497), 11 (p = 0.035) and two (p = 0.034). With simple and low cost measures, like the pharmaceutical intervention, it is possible to improve the patient adherence to the oral treatment of CML.